Immunic
IMUX
47 hedge funds and large institutions have $1.22M invested in Immunic in 2018 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 14 increasing their positions, 17 reducing their positions, and 11 closing their positions.
629% more call options, than puts
Call options by funds: $51K | Put options by funds: $7K
0.01% less ownership
Funds ownership: 0.05% → 0.04% (-0.01%)
13% less funds holding
Funds holding: 54 → 47 (-7)
18% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 17
49% less capital invested
Capital invested by funds: $2.39M → $1.22M (-$1.17M)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AQR Capital Management
Greenwich,
Connecticut
|
+$160K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$99.7K |
| 3 |
SG Americas Securities
New York
|
+$58.4K |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$49.8K |
| 5 |
VF
Virtu Financial
New York
|
+$49.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$231K |
| 2 |
Millennium Management
New York
|
-$219K |
| 3 |
BlackRock
New York
|
-$143K |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$91K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$79.7K |
IMUX Hedge Fund Activity: Q4 2018 in Review
47 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q4 2018, worth a combined $1.22M — down 49% from $2.39M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of IMUX and 5 opened new positions — a net loss of 6 holders — while 17 trimmed existing stakes and 14 added.
The largest buyer was AQR Capital Management, adding an estimated $160K. The largest seller was Vanguard Group, cutting an estimated $231K.
- 47 institutional investors held Immunic (IMUX) as of Q4 2018, down from 54 in Q3 2018.
- Funds reported $1.22M of Immunic stock for Q4 2018, down 49% quarter-over-quarter.
- 5 funds opened new Immunic positions in Q4 2018 and 11 closed out, a net change of -6 holders.
- The largest Immunic buyer in Q4 2018 was AQR Capital Management, an estimated $160K added.
- The largest Immunic seller in Q4 2018 was Vanguard Group, an estimated $231K sold.
Based on aggregated 13F filings for Q4 2018.